OMNI 360 Wealth Inc. buys 264 shares of Eli Lilly and Company (NYSE:LLY)

OMNI 360 Wealth Inc. acquired a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) in the second quarter, HoldingsChannel.com reports. The fund acquired 264 shares of the company’s stock, valued at approximately $239,000.

A number of other hedge funds have also recently bought and sold shares of the company. Tidemark LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $29,000. Core Wealth Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares in the last quarter. Lynx Investment Advisory purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $32,000. Frank Rimerman Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $37,000. Finally, St. Johns Investment Management Company LLC boosted its holdings in shares of Eli Lilly and Company by 123.3% during the 4th quarter.St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after purchasing an additional 37 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s shares.

Indoor activity

In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of Eli Lilly and Company stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $809.21, for a total value of $74,902,905.23. Following the sale, the insider now owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The sale was disclosed in a legal filing with the SEC, which can be accessed via this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of the company’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the sale, the insider now owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The transaction was disclosed in a legal filing with the SEC, which can be accessed via this link. Also, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Insiders sold a total of 1,214,704 shares of company stock valued at $1,066,841,316 over the last quarter. Corporate insiders own 0.13% of the company’s shares.

Analysts set new price targets

A number of brokerages have recently issued reports on LLY. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, August 5th. Argus upped their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday. Morgan Stanley reaffirmed an “overweight” rating and set a $1,023.00 price objective on shares of Eli Lilly and Company in a research report on Friday, July 5th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their target price for the company from $725.00 to $1,025.00 in the -a research report from Monday, August 12. Two equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $956.88, according to MarketBeat .

Get the latest stock report on Eli Lilly and Company

Eli Lilly and Company Stock Performance

NYSE LLY traded down $2.47 during trading on Monday, reaching $919.65. The company’s stock had a trading volume of 803,238 shares, compared to its average volume of 3,083,729. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03, and a current ratio of 1.35. The firm has a market cap of $874.04 billion, a price-to-earnings ratio of 135.44, a P/E/G ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $966.10. The company’s fifty day moving average price is $878.93 and its 200 day moving average price is $806.28.

Eli Lilly and Company announces dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents an annualized dividend of $5.20 and a dividend yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 15. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Profile

(Free report)

Eli Lilly and Company discovers, develops and markets human pharmaceutical products worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R and Humulin U-500 for diabetes; Jardiance, Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured stories

Want to see what other hedge funds own LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Get news and reviews for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.